AAV.U7-AS2

N/A

Report date: 2025/03/14 16:43:37

Base Information

Drug NameAAV.U7-AS2
Drug Alias NameAAV.U7-ex44exon 44-skipping antisense oligonucleotide therapy (Alcyone Therapeutics/The Ohio State University/Nationwide Children's Hospital/University of California)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionDMD gene modulators
TargetsDystrophin
Therapy Area/IndicationsMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe Ohio State University Wexner Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesAlcyone Lifesciences IncThe Ohio State University Wexner Medical CenterAbigail Wexner Research Institute +[4] 
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Duchenne
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A